Recruiting
Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Sponsor:

UCLA

Code:

NCT05009992

Conditions

Diffuse Intrinsic Pontine Glioma

Diffuse Midline Glioma, H3 K27M-Mutant

Recurrent Diffuse Intrinsic Pontine Glioma

Recurrent Diffuse Midline Glioma, H3 K27M-Mutant

Recurrent WHO Grade III Glioma

Eligibility Criteria

Sex: All

Age: 2 - 39

Healthy Volunteers: Not accepted

Interventions

ONC201

Radiation Therapy

Paxalisib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2025-03-25.